Cough syrup deaths: SC rejects PIL seeking CBI probe, safety review

The bench, which was initially of the view that the notice should be issued, later dismissed it

Supreme Court, SC
A bench comprising Chief Justice B R Gavai and Justices Ujjal Bhuyan and K Vinod Chandran dismissed the PIL. (Photo:PTI)
Press Trust of India New Delhi
1 min read Last Updated : Oct 10 2025 | 12:10 PM IST

The Supreme Court on Friday dismissed a PIL seeking an inquiry and systemic reform in drug safety mechanisms in the wake of deaths of children in Madhya Pradesh and Rajasthan allegedly due to consumption of toxic cough syrups.

A bench comprising Chief Justice B R Gavai and Justices Ujjal Bhuyan and K Vinod Chandran dismissed the PIL filed by lawyer Vishal Tiwari after Solicitor General Tushar Mehta objected to it.

The top law officer said the petitioner reads the newspaper and rushes to the court.

The bench, which was initially of the view that the notice should be issued, later dismissed it.

Mehta said he was not appearing for any state at the moment but the seriousness with which states like Tamil Nadu and Madhya Pradesh are taking actions cannot be undermined.

Moreover, there are proper law enforcement mechanisms in states, he added.

The bench asked Tiwari as to how many PILs he has filed so far in the top court and on being told that he has moved eight to 10 such pleas so far, the bench dismissed the instant petition.

"Dismissed," the CJI said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Supreme CourtCough syrupPharma sector

First Published: Oct 10 2025 | 12:10 PM IST

Next Story